Download fulltext HTML
Mirghani, H. O., Abdul Khalig Alyoussef, A., & Mohammed, O. S. (2020). The relationship between dyslipidemia and lupus nephritis in systemic lupus erythematosus patients attending a Saudi Rheumatic Center, Tabuk. Sudan Journal of Medical Sciences (SJMS), 15(1), 10-19. https://doi.org/10.18502/sjms.v15i1.6697

https://doi.org/10.18502/sjms.v15i1.6697

statistics

  • 1093 Abstract Views
  • 341 PDF Views
  • 0 HTML Views
  • Cited by 2 articles

authors

  • Hyder Osman Mirghani

    Hyder Osman Mirghani

    Department of Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Kingdom of Saudi Arabia
  • Abdullah Abdul Khalig Alyoussef

    Abdullah Abdul Khalig Alyoussef

    Department of Clinical Pharmacy, Faculty of Pharmacy, University of Tabuk, Tabuk, Kingdom of Saudi Arabia
  • Osama Salih Mohammed

    Osama Salih Mohammed

    King Fahd Specialist Hospital, Al Qadsiyyah, Tabuk, Saudi Arabia

Published Date

  • Mar 31, 2020

The relationship between dyslipidemia and lupus nephritis in systemic lupus erythematosus patients attending a Saudi Rheumatic Center, Tabuk

Sudan Journal of Medical Sciences (SJMS) / Sudan JMS: Volume 15 (2020), Issue No. 1 / Pages 10-19

Abstract

Background: There is an increasing awareness of the role of dyslipidemia in lupus nephritis patients, no researchers have studied dyslipidemia in systemic lupus erythematosus (SLE) in Tabuk. In this study, we aimed to investigate the association between dyslipidemia and lupus nephritis in Tabuk, Saudi Arabia.


Methods: This cross-sectional comparative longitudinal hospital-based study was conducted at a rheumatic clinic in the North West Armed Force Hospital (NWAFH) during the period April 2014–June 2015. Seventy-three patients diagnosed with SLE were invited to participate in the study. All participants were required to sign a written informed consent, following which they were interviewed using a structured questionnaire. Data collected include demographic data, clinical characteristics, fasting lipid profile, renal function tests, urine analysis, antinuclear antibody, anti-double-stranded antibodies, complement levels, serum albumin, anticardiolipin, ant bodies, and antiphospholipid antibodies. Lupus nephritis was ascertained by renal biopsy. The research was approved by the ethical committees of both the University of Tabuk and the NWAFH and data were analyzed using the Statistical Package for Social Sciences (SPSS).


Results: Out of 73 patients with SLE, 86.3% were females with a mean age of  34 ± 6.4 years. Lupus nephritis was evident in 26% of the patients, proteinuria in 44.1%, high total cholesterol in 17.8%, high low-density lipoprotein in 15.1%, high triglycerides in 27.3%, and low high-density lipoproteins in 52.1%. Patients with lupus nephritis had high total cholesterol, high LDL, high TG, and low HDL than those without lupus nephritis P-value < 0.05.


Conclusion: Dyslipidemia was more common among patients with SLE nephritis, and an aggressive treatment is recommended to reduce this serious complication. The relatively small size of the study group and the fact that the study was conducted at a single tertiary center are the limitations of this study.


Keywords: dyslipidemia, lupus nephritis, Saudi Arabia

References
[1] Angélica Sinicato, N., Aparecida da Silva Cardoso, P., and Appenzeller, S. (2013). Risk factors in cardiovascular disease in systemic lupus erythematosus. Current Cardiology Reviews, vol. 9, no. 1, pp. 15–19. DOI:10.2174/157340313805076304

[2] Hak, A. E., Karlson, E. W., Feskanich, D., et al. (2009). Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis & Rheumatology, vol. 61, no. 10, pp. 1396–1402.

[3] Schoenfeld, S. R., Kasturi, S., Costenbader, K. H. (2013). The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Seminars in Arthritis and Rheumatism, vol. 43, no. 1, pp. 77–95.

[4] Zeller, C. B. and Appenzeller, S. (2008). Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Current Cardiology Reviews, vol. 4, no. 2, pp. 116–122.

[5] Willerson, J. T. and Ridker, P. M. (2004). Inflammation as a cardiovascular risk factor. Circulation, vol. 109, no. 21, pp. 2–10.

[6] Abou-Raya, A. and Abou-Raya, S. (2006). Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmunity Reviews, vol. 5, no. 5, pp. 331–337.

[7] Machado, D., Sarni, R. O., Abad, T. T., et al. (2017). Lipid profile among girls with systemic lupus erythematosus. Rheumatology International, vol. 37, no. 1, pp. 43–48.

[8] Chong, Y. B., Yap, D. Y., Tang, C. S., et al. (2011). Dyslipidaemia in patients with lupus nephritis. Nephrology, vol. 16, no. 5, pp. 511–517.

[9] Hochberg, M. C. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatology, vol. 40, no. 9, p. 1725.

[10] Siripaitoon, B., Osiri, M., Vongthavaravat, V., et al. (2004). The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus. Lupus, vol. 13, no. 12, pp. 961–968.

[11] Chan, T. M. (2006). Determinants of patient survival in systemic lupus erythematosus – focusing on lupus nephritis. Ethnicity & Disease, vol. 16, no. 2, pp. S2–S66.

[12] Basulaiman, M., El Bcheraoui, C., Tuffaha, M., et al. (2014). Hypercholesterolemia and its associated risk factors — Kingdom of Saudi Arabia, 2013. Annals of Epidemiology, vol. 24, no. 11, pp. 801–808. DOI: 10.1016/j.annepidem.2014.08.001

[13] Wijaya, L. K., Kasjmir, Y. I., Sukmana, N., et al. (2005). The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Medica Indonesiana, vol. 37, no. 3, pp. 132–144.

[14] Formiga, F., Meco, J. F., Pinto, X., et al. (2001). Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus, vol. 10, no. 5, pp. 359–363.

[15] Tyrrell, P. N., Beyene, J., Benseler, S. M., et al. (2007). Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. Journal of Rheumatology, vol. 34, no. 10, pp. 2112–2119.

[16] Kashef, S., Ghaedian, M. M., Rajaee, A., et al. (2007). Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies. Rheumatology International, vol. 27, no. 3, pp. 235–241.

[17] Tisseverasinghe, A., Lim, S., Greenwood, C., et al. (2006). Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis & Rheumatology, vol. 54, no. 7, pp. 2211–2219.

[18] Lewis, M. J., Malik, T. H., Fossati-Jimack, L., et al. (2012). Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis & Rheumatology, vol. 64, no. 8, pp. 2707–2718. DOI:10.1002/art.34451

[19] Olusi, S. O. and George, S. (2011). Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vascular Health and Risk Management, vol. 7, pp. 75–80. DOI:10.2147/VHRM.S17015